Search bioRxiv⌕ Search

Biology subjects

Schnaar, R. L.

Publications and source records attributed to Schnaar, R. L..

2 recordsLinked to original sources

The Proteome as a Lectome: Predictions from Deep Learning Propose Substantial Protein-Carbohydrate Interplay

It is a grand challenge to identify all the protein - carbohydrate interactions in an organism. Direct experiments would require extensive libraries of glycans to definitively distinguish binding from non-binding proteins. Computational screening of proteins for carbohydrate-binding provides an attractive and ultimately testable alternative. Recent computational techniques have focused primarily on which protein residues interact with carbohydrates or which carbohydrate species a protein binds to. Current estimates label 1.5 to 5% of proteins as carbohydrate-binding proteins; however, 50-70% of proteins are known to be glycosylated, suggesting a potential wealth of proteins that bind to carbohydrates. We therefore developed a novel dataset and neural network architecture, named Protein interaction of Carbohydrates Predictor (PiCAP), to predict whether a protein non-covalently binds to a carbohydrate. We trained PiCAP on a dataset of known carbohydrate binders, and we selected proteins that we identified as likely not to bind carbohydrates, including DNA-binding transcription factors, cytoskeletal components, selected antibodies, and selected small-molecule-binding proteins. PiCAP achieves a 90% balanced accuracy on protein-level predictions of carbohydrate binding/non-binding. Using the same dataset, we developed a model named Carbohydrate Protein Site Identifier 2 (CAPSIF2) to predict protein residues that interact non-covalently with carbohydrates. CAPSIF2 achieves a Dice coefficient of 0.57 on residue-level predictions on our independent test dataset, outcompeting all previous models for this task. To demonstrate the biological applicability of PiCAP and CAPSIF2, we investigated cell surface proteins of human neural cells and further predicted the likelihood of three proteomes, notably E. coli, M. musculus, and H. sapiens, to bind to carbohydrates. PiCAP predicts that approximately 35-40% of proteins in these proteomes bind carbohydrates, indicating a substantial interplay of protein-carbohydrate interactions for cellular functionality. Significance StatementThe totality of carbohydrate-protein interactions remains elusive, in part due to the inability to test proteomes versus glycomes in a high throughput manner. Here we show the first high-throughput methodology to predict protein-carbohydrate interactions at proteomic scales by using structural and sequence information. This information will allow scientists to target predicted protein-carbohydrate interactions to better determine how the elusive carbohydrate biomolecules play roles in all cellular functions.

bioinformatics↗

Amyloid-beta and tau pathologies are both necessary to induce novel stage-specific microglia subtypes during Alzheimer's disease progression.

It is unknown whether specific microglia are selectively induced by amyloid-{beta} (A{beta}), tau pathologies, or both in combination. To address this, we use single-cell RNA-sequencing to profile mice bearing both A{beta} and tau pathologies during Alzheimers disease (AD) progression. We identify novel microglia subtypes induced in a disease stage-specific manner. We show that during early-stage disease, interferon signaling induces a subtype of microglia termed EADAM. During late-stage disease, a second microglia subtype termed LADAM is detected. While EADAM and LADAM-like microglia are observed in other neurodegenerative models, the magnitude and composition of subtype markers are distinct from microglia observed with AD-like pathology. The pattern of EADAM- and LADAM-associated gene expression is observed in microglia from human AD, during the early and late stages of disease, respectively. Furthermore, we observe that several siglec genes are selectively expressed in either EADAM or LADAM. Siglecg is expressed in white-matter-associated LADAM, and expression of the human orthologue of Siglecg is progressively elevated in AD-stage-dependent manner but not shown in non-AD tauopathy. Our findings imply that both A{beta} and tau pathologies are required for disease stage-specific induction of EADAM and LADAM.

neuroscience↗